Retatrutide Complete Guide (I)

What is Retatrutide?

Retatrutide(R & D code LY3437943) is an injectable polypeptide drug developed by Eli Lilly , which is a new generation of incretin (incretin) weight loss and hypoglycemic candidate drug. Its most striking feature is the "triple agonist" (triple agonist) design: a single molecule can simultaneously activate three different metabolic receptors: glucagon-like peptide -1 receptor (GLP-1), glucose-dependent insulinotropic polypeptide receptor (GIP) and glucagon receptor .

Structurally, Retatrutide is a fatty acid-modified synthetic polypeptide whose backbone is based on the glucagon/GLP-1 family sequence and which binds to albumin via a side chain fatty acid for extended half-life. This modification makes it possible to achieve a dosing frequency of once weekly subcutaneous injection, which is consistent with the GLP-1 drug delivery methods currently on the market and facilitates long-term use.

The background for the development of the Retatrutide stems from the rapid evolution of the field of obesity treatment. First-generation drugs such as semaglutide are single-GLP-1 agonists that can achieve about 15-17% weight loss; second-generation telpotide (tirzepatide) is a dual GLP-1/GIP agonist that can increase weight loss to about 20-22%. The Retatrutide represents a further extension of the "multi-receptor synergy" strategy, which attempts to break through the ceiling of weight loss by overlaying a third target.

It is worth emphasizing that Retatrutide is still in the clinical research stage, it has not been approved by any regulatory body for human treatment.. This article is for educational purposes only and does not constitute medical advice. Any decisions related to weight management or metabolic disease should be made under the guidance of a qualified medical professional. Outside of clinical trials, Retatrutide are also sold in Europe in the form of pre-filled pens for research use.

How do triple agonists work?

To understand the mechanism of Retatrutide, we need to understand the physiological role of each of the three receptors it targets. These three pathways play complementary roles in energy balance and blood sugar regulation, and the core innovation of the Retatrutide is to integrate them into the same molecule to create a synergistic effect.

GLP-1 receptor agonism the basic mechanism. Activation of GLP-1 receptors can enhance glucose-dependent insulin secretion, inhibit the inappropriate release of glucagon, delay gastric emptying, and act on the hypothalamic appetite center to enhance satiety and reduce food intake. This is the main source of the weight loss effect of selmegraglutide and tilpotide.

GIP receptor agonism provides a second layer of action. GIP is also an incretin that synergistically enhances postprandial insulin secretion and is thought to improve adipose tissue metabolic function and insulin sensitivity. The combined effect of GIP and GLP-1 is one of the key reasons why telpotide is superior to single GLP-1 drugs.

glucagon receptor agonism it is the decisive third target that distinguishes Retatrutide from tilpotide. Traditionally, glucagon elevates blood sugar, but moderate activation of the glucagon receptor increase energy expenditure (increase basal metabolic rate), promote lipolysis (lipolysis) and improve liver fat content. Its potential glycemic effect is offset by the powerful GLP-1/GIP insulinotropic effect, resulting in a net effect of weight loss while maintaining glycemic control.

This "three-pronged" design means that the Retatrutide not only works from the intake side (reducing appetite and eating), but also from the consumption side (increasing energy expenditure and fat burning). It should be noted that the addition of the glucagon pathway also brings additional monitoring requirements for heart rate, blood pressure, and glucose metabolism.

What are the results of Phase II clinical trials?

Retatrutide of the most talked-about data comes from a phase II clinical trial published in the New England Journal of Medicine (NEJM) in 2023. This randomized, double-blind, placebo-controlled study enrolled obese adults and evaluated the weight loss and safety of different doses of Retatrutide over 48 weeks.

The results show obvious dose-dependent weight reduction effect. In the highest dose (12 mg per week) group, the average weight of subjects at week 48 decreased from baseline by about 24%. This number is a rare high level in clinical studies of weight loss drugs, and the weight loss of some subjects is even close to the effect range of some weight loss surgery (bariatric surgery).

The following table summarizes the approximate weight loss performance of the key dose groups in the Phase II trial:

in addition to weight loss, the trial also observed improvements in metabolic parameters, including blood glucose, lipids and blood pressure parameters. In a parallel phase II study in patients with type 2 diabetes, Retatrutide also showed a significant reduction in glycated hemoglobin (HbA1c), suggesting its potential in blood glucose management.

It is worth taking a cautious view that the weight loss curve in the phase II trial has not yet shown a significant plateau at 48 weeks, which means that the final weight loss in the longer course of treatment is still unknown. At the same time, the phase II sample size is relatively limited, and key questions such as long-term safety, cardiovascular outcomes, and weight rebound after discontinuation need to be answered by larger phase III trials. Thus, these data, while encouraging, are still preliminary research evidence it should not be interpreted as an established clinical conclusion.

Phase III trial results (TRIUMPH items)

between December 2025 and November 2026, Lilly published the results of the first phase III trials in Retatrutide. All trials randomly assigned adults to either weekly Retatrutide or placebo, with diet and exercise and up-regulation from a lower starting level. Results are reported in two ways of analysis: therapeutic strategy (treatment-regimen) Estimated goals all randomizations were included, including those who stopped the drug; efficacy (efficacy) Estimated Target to estimate the effect of those who adhere to the treatment, the value is higher.

results other than weight: in TRIUMPH-4, the WOMAC scale-assessed knee pain dropped by up to 4.5 points, compared with a 2.4-point drop in the placebo group. TRIUMPH-1 also met the primary endpoint of knee osteoarthritis pain and apnea-hypopnea index in subjects with obstructive sleep apnea. In TRIUMPH-2, HbA1c fell 1.4 to 1.6 percentage points from 7.7 percent of baseline and 0.2 percentage points in the placebo group.

Security: the most common adverse events were gastrointestinal reactions (nausea, diarrhea, constipation, vomiting), which increased with treatment level. There were more reports of paresthesia (skin abnormalities or discomfort) than in the placebo group: up to 20.9 percent versus 0.7 percent in TRIUMPH-4 and about 6 percent versus 1 percent in TRIUMPH-3. The rate of discontinuation due to adverse events was 18.2 percent in the TRIUMPH-4 group, 13.5 percent in the TRIUMPH-3 group, and about 4 to 5 percent in the placebo group. TRIUMPH-3 was not a cardiovascular outcome trial and the number of major cardiovascular events was too small to be conclusive.

Follow-up progress: lilly said it plans to submit the Retatrutide's marketing application to the FDA in the first quarter of 2027. Lilly and the FDA are in litigation over whether Retatrutide should be reviewed under biologics, which will determine the type of application. Pending any regulatory approval, Retatrutide remains an investigational drug. Retatrutide not in within the scope of the US HHS Enforcement Discretion Policy issued on October 28, 2026 for six additional polypeptides (BPC-157, MOTS-c, Epitalon, Semax and KPV).